This page is updated frequently with new Bowel-related patent applications.
| Naphthyridine compounds as jak kinase inhibitors|
Wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of jak kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat inflammatory bowel diseases, and processes and intermediates useful for preparing such compounds..
| Drug delivery compositions and methods of use|
The present invention provides a composition comprising a disaccharide where at least one of the hydroxyl groups of the disaccharide is attached to a linker. The terminal portion of the linker also includes a drug that is attached via a functional group that is capable of releasing the drug in vivo.
The Arizona Board Of Regents On Behalf Of The University Of Arizona
| Synthetic composition and treating irritable bowel syndrome|
The application relates to synthetic compositions containing one or more human milk mono- or oligosaccharides for use treating irritable bowel syndrome.. .
|Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating e. coli induced inflammatory bowel diseases such as crohn's disease|
Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating e. Coli induced inflammatory bowel diseases such as crohn's disease..
Inserm (institut National De La Sante Et De La Recherche Medicale)
|Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders|
The invention provides novel guanylate cyclase-c agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cgmp-dependent phosphodiesterase.
Synergy Pharmaceuticals, Inc.
|Methods for treating autism spectrum disorder and associated symptoms|
The present disclosure relates to compositions and methods for treating autism spectrum disorder (asd) by restoring an asd patient's gut microbiota. These methods can be used with asd patient with or without ongoing gastrointestinal symptoms.
|Methods and systems for feeding readiness diagnosis|
An aspect of the invention described herein includes a method for a digestion diagnosis of a subject. The method includes obtaining electrogastrogram (egg), bowel sound and nirs signals from one or more sensors positioned about an abdominal region of a subject, removing artifacts from the signals to obtain conditioned signal data, and determining a digestion condition or feeding readiness of the subject based at least in part on the conditioned signal data..
University Of Florida Research Foundation, Inc.
|Heterocyclic compounds and their uses|
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
|Compositions for fecal floral transplantation and methods for making and using them and device for delivering them|
This application provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments, and methods for making, storing and using them, including storage, including long term storage, at ambient temperature. Compositions provided herein are useful for treating various diseases or conditions such as autism spectrum disorder, crohn's disease, ulcerative colitis, irritable bowel syndrome, and recurrent or primary c.
|Use of compounds that are able to increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced igf-1 serum level in humans and animals|
The present disclosure relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (igf-1) for the preparation of a therapeutical composition, in particular, in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome. The same composition can also be used by patients suffering from depression, alzheimer disease, irritated bowel syndrome, osteoporosis, type 2 diabetes, or for anti-aging, immune therapy and recovery after exercise.
Bowel evacuation aid
A bowel evacuation aid is provided. Generally, the apparatus includes an elongated member having a cross sectional profile of a lengthwise cross section of an american football with one end flattened, a first side having grooves for heat redistribution and a second side having a handhold depression..
Turdle Time, Llc.
Evacuation assist device and methods
A device for human female vaginal wall self-manipulation is provided that assists in evacuation of the bladder and/or bowel. Methods are also provided in which the inventive evacuation device is utilized to evacuate the bladder and/or the bowel..
Lgo Medical, Llc
Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases
Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods.
Curelab Oncology, Inc.
Recombinant lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses
Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface.
Suppository insertion tool
A suppository insertion tool is a device utilized to administer a suppository within the body as well as to detect the presence of an obstruction within the bowels. A semi-rigid plunger member is telescopically engaged into a tubular semi-rigid sleeve member.
Leptin in immune modulation
The present invention relates to methods for treating inflammatory bowel disease and other indications by inhibiting leptin activity.. .
Enzo Therapeutics. Inc. C/o Enzo Biochem, Inc.
Polypeptides targeting glycosylated muc2 proteins, methods of synthesis, their nucleic acids and uses thereof
The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence p1(xa)p3(xb)p5(xc)p6(xd)p7 (seq id no: 1), presenting specific patterns. The polypeptides of the invention target glycosylated muc2 proteins.
Tetrahydro-pyrimidoazepines as modulators of trpv1
Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as trpv1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by trpv1.
Janssen Pharmaceutica Nv
3-(5-chloro-2-oxobenzo[d]oxazol-3(2h)-yl) propanoic acid derivatives as kmo inhibitors
Wherein r1, x and r3 are defined in the specification, useful in the treatment of disorders mediated by kmo such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (sirs), huntington's disease, alzheimer's disease, spinocerebellar ataxias, parkinson's disease, aids-dementia complex, amylotrophic lateral sclerosis (als), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.. .
Fumarate compounds, pharmaceutical compositions thereof, and methods of use
Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .
Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of erbb4.. .
Children's Hospital Los Angeles
Conjugates of a phospholipid and a drug for the treatment of inflammatory bowel disease
Conjugates of drugs suitable for use in the treatment of inflammatory bowel disease and phospholipids, and their use in the treatment of inflammatory bowel disease, are disclosed. The disclosed conjugates serve as targeted prodrugs which are suitable for oral administration, and which are capable of releasing the drug selectively at the diseased tissue upon activation by pla2..
Ben-gurion University Of The Negev Research And Development Authority
Fungal mycobiome as probiotics, diagnostics and therapeutics
The present invention relates to methods of using fungal mycobiome as a means of treating and/or diagnosing diseases in a subject. In one embodiment, the present invention provides a method of diagnosing inflammatory bowel disease based on the composition of fungal strains present in the gut of a subject, and treating the subject by administering a probiotic biotherapy.
Cedars-sinai Medical Center
Inflammatory Bowel Disease
Irritable Bowel Syndrome
Follow us on Twitter
This listing is a sample listing of patent applications related to Bowel for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bowel with additional patents listed. Browse our RSS directory or Search for other possible listings.